Disaggregated Revenues

6 Months Ended

Jun. 30, 2019

Disaggregation of Revenue [Abstract]

Disaggregated Revenues

Disaggregated Revenues

The following table summarizes the disaggregation of revenues by nature, in thousands of dollars:

	Three Months ended June 30,				Six Months ended June 30,
	2019		2018		2019		2018
	(unaudited)				(unaudited)
Net product sales
Trokendi XR	$	78,964	$	76,474	$	142,657	$	147,029
Oxtellar XR	23,394		20,556		42,800		39,121
Total net product sales	$	102,358	$	97,030	$	185,457	$	186,150
Royalty revenues	2,337		1,758		4,712		3,067
Licensing revenues	—		750		—		750
Total revenues	$	104,695	$	99,538	$	190,169	$	189,967

The majority of the Company’s product sales are to pharmaceutical wholesalers/distributors who, in turn, sell the Company's products to chain and independent pharmacies, hospitals and other customers. Three pharmaceutical wholesalers/distributors collectively accounted for more than 90% of the Company’s total net product sales and accounts receivables as of and for the three and six month periods ended June 30, 2019 and 2018, respectively.

The Company recognized non-cash royalty revenue of $1.8 million and $3.4 million for the three and six month periods ended June 30, 2019, respectively. The Company recorded non-cash royalty revenue of $1.5 million and $2.8 million for the three and six month periods ended June 30, 2018, respectively.

No milestone revenue was recorded for the three and six month periods ended June 30, 2019. The Company recorded $0.8 million in milestone revenue for both the three and six month periods ended June 30, 2018.

For the three and six month periods ended June 30, 2019, revenues recognized from performance obligations related to prior periods (e.g., due to changes in transaction price) were not material, in the aggregate, to either Net product sales or Royalty revenues.